advertisement
Levin LA 39
Showing records 1 to 25 | Display only abstracts from Levin LA in IGR 25-1122770 Maculopapillary Bundle Degeneration in Optic Neuropathies
Lambiri DW; Levin LA
Current neurology and neuroscience reports 2024; 24: 203-218 (IGR: 25-1)
96240 Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma
Geva M; Gershoni-Emek N; Naia L; Ly P; Mota S; Rego AC; Hayden MR; Levin LA
Scientific reports 2021; 11: 21975 (IGR: 22-3)
74539 Glaucoma and the brain: Trans-synaptic degeneration, structural change, and implications for neuroprotection
Lawlor M; Danesh-Meyer H; Levin LA; Davagnanam I; De Vita E; Plant GT
Survey of Ophthalmology 2018; 63: 296-306 (IGR: 19-1)
70376 Translational Pharmacology in Glaucoma Neuroprotection
Levin LA
Handb Exp Pharmacol 2017; 242: 209-230 (IGR: 18-2)
70412 Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma
De Moraes CG
Progress in Retinal and Eye Research 2017; 56: 107-147 (IGR: 18-2)
70733 Neuroprotection for glaucoma: Requirements for clinical translation
Levin LA; Crowe ME
Experimental Eye Research 2017; 157: 34-37 (IGR: 18-2)
70412 Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma
Liebmann JM
Progress in Retinal and Eye Research 2017; 56: 107-147 (IGR: 18-2)
70733 Neuroprotection for glaucoma: Requirements for clinical translation
Quigley HA
Experimental Eye Research 2017; 157: 34-37 (IGR: 18-2)
70412 Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma
Levin LA
Progress in Retinal and Eye Research 2017; 56: 107-147 (IGR: 18-2)
70733 Neuroprotection for glaucoma: Requirements for clinical translation
Experimental Eye Research 2017; 157: 34-37 (IGR: 18-2)
51275 Solving the lost in translation problem: Improving the effectiveness of translational research
Ergorul C; Levin LA
Current opinion in pharmacology 2013; 13: 108-114 (IGR: 14-3)
46550 A cell-permeable phosphine-borane complex delays retinal ganglion cell death after axonal injury through activation of the pro-survival extracellular signal-regulated kinases 1/2 pathway
Almasieh M; Lieven CJ; Levin LA; Di Polo A
Journal of Neurochemistry 2011; 118: 1075-1086 (IGR: 13-3)
26463 Neuroprotection against superoxide anion radical by metallocorroles in cellular and murine models of optic neuropathy
Kanamori A; Catrinescu M-M; Mahammed A; Gross Z; Levin LA
Journal of Neurochemistry 2010; 114: 488-498 (IGR: 12-3)
26166 In vivo imaging of retinal ganglion cell axons within the nerve fiber layer
Kanamori A; Catrinescu MM; Traistaru M; Beaubien R; Levin LA
Investigative Ophthalmology and Visual Science 2010; 51: 2011-2018 (IGR: 12-2)
26255 Serial multifocal electroretinograms during long-term elevation and reduction of intraocular pressure in non-human primates
Michael Nork T; Kim CB; Heatley GA; Kaufman PL; Lucarelli MJ; Levin LA; Ver Hoeve JN
Documenta Ophthalmologica 2010; 120: 273-289 (IGR: 12-2)
24019 Neuroprotection: extrapolating from neurologic diseases to the eye
Danesh-Meyer HV; Levin LA
American Journal of Ophthalmology 2009; 148: 186-191 (IGR: 11-3)
21959 Model systems for experimental studies: retinal ganglion cells in culture
Goodyear E; Levin LA
Progress in Brain Research 2008; 173: 279-284 (IGR: 10-4)
21160 History of neuroprotection and rationale as a therapy for glaucoma
Levin LA; Peeples P
American Journal of Managed Care 2008; 14: S11-S14 (IGR: 10-2)
20581 The neurobiology of cell death in glaucoma
Vrabec JP; Levin LA
Eye 2007; 21: S11-S14 (IGR: 10-1)
19942 Induction of axon and dendrite formation during early RGC-5 cell differentiation
Lieven CJ; Millet LE; Hoegger MJ; Levin LA
Experimental Eye Research 2007; 85: 678-683 (IGR: 9-4)
19575 Cost of patients with primary open-angle glaucoma: A retrospective study of commercial insurance claims data
Lee PP; Levin LA; Walt JG; Chiang T; Katz LM; Dolgitser M; Doyle JJ; Stern LS
Ophthalmology 2007; 114: 1241-1247 (IGR: 9-3)
18034 Axonal loss and neuroprotection in optic neuropathies
Levin LA
Canadian Journal of Ophthalmology 2007; 42: 403-408 (IGR: 9-2)
18030 The impact of glaucoma coding in a large claims database
Lee PP; Levin LA; Walt JG; Chiang TH; Doyle JJ; Stern LS; Dolgitser M
American Journal of Ophthalmology 2007; 143: 867-870 (IGR: 9-2)
15264 Synthesis and characterization of a novel class of reducing agents that are highly neuroprotective for retinal ganglion cells
Schlieve CR; Tam A; Nilsson BL; Lieven CJ; Raines RT; Levin LA
Experimental Eye Research 2006; 83: 1252-1259 (IGR: 8-4)
14040 Biochemical activity of reactive oxygen species scavengers do not predict retinal ganglion cell survival
Schlieve CR; Lieven CJ; Levin LA
Investigative Ophthalmology and Visual Science 2006; 47: 3878-3886 (IGR: 8-3)